People In The News: Actavis’ Upcoming Topside Line-Up; Changes At Ocera, Jazz, Nektar, Amgen
Actavis has organized its management team to take the reins after the Forest acquisition closes, plus more personnel announcements in this month’s column.
You may also be interested in...
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.